PDPN and lung cancer: Oksana Kowalczuk’s study also manifested that PDPN transcriptional downregulation was more significant in high-graded tumors (G3 or G4) compared with low-graded ones (G1 or G2) (P = 0.049) among I-III lung cancer patients [35], which coincides with our results.